Phenotypes associated with this allele

• Allele Symbol: Tg(Mpz-cre)3Brn
• Allele Name: transgene insertion 3, Anton Berns
• Allele ID: MGI:3047148
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Nf2^tm2Gth/Nf2^tm2Gth Trp53^tm1Brd/Trp53^+ Tg(Mpz-cre)3Brn/0	involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N	MGI:3850409
cn2	Nf2^tm2Gth/Nf2^+ Trp53^tm1Brd/Trp53^+ Tg(Mpz-cre)3Brn/0	involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N	MGI:3850410
cn3	Nf2^tm2Gth/Nf2^tm2Gth Tg(Mpz-cre)3Brn/0	involves: 129P2/OlaHsd * FVB/N	MGI:3850390
cn4	Nf2^tm1Gth/Nf2^tm2Gth Tg(Mpz-cre)3Brn/0	involves: 129P2/OlaHsd * FVB/N	MGI:3850395

Genotype
MGI:3850409

cn1

• Allelic Composition: Nf2^tm2Gth/Nf2^tm2Gth; Trp53^tm1Brd/Trp53⁺; Tg(Mpz-cre)3Brn/0
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased survivor rate ( J:92413 )

premature death ( J:92413 )

• 4 of 12 mice die prematurely due to malignant peripheral nerve sheath tumors, 3 of which are 5 months old

neoplasm

increased neurofibrosarcoma incidence ( J:92413 )

• in 4 of 12 mice

nervous system

increased neurofibrosarcoma incidence ( J:92413 )

• in 4 of 12 mice

Genotype
MGI:3850410

cn2

• Allelic Composition: Nf2^tm2Gth/Nf2⁺; Trp53^tm1Brd/Trp53⁺; Tg(Mpz-cre)3Brn/0
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N

mortality/aging

premature death ( J:92413 )

• mice exhibit a decrease in survival rate when the Nf2 and Trp53 alleles are carried in cis as opposed to trans, but live longer than conditional mutants carrying Tg(P0-Cre)2Gth

neoplasm

increased neurofibrosarcoma incidence ( J:92413 )

• between 3.5 and 13.5 months,19% of mice develop malignant peripheral nerve sheath tumors when the Nf2 and Trp53 alleles are carried in cis

• however, no tumors form in mice when the Nf2 and Trp53 alleles are carried in trans

increased skeletal tumor incidence ( J:92413 )

• when the Nf2 and Trp53 alleles are carried in trans mice develop osteogenic tumors not restricted to neural crest-derived bone

increased osteosarcoma incidence ( J:92413 )

• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis

increased osteoma incidence ( J:92413 )

• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis

skeleton

increased skeletal tumor incidence ( J:92413 )

• when the Nf2 and Trp53 alleles are carried in trans mice develop osteogenic tumors not restricted to neural crest-derived bone

increased osteosarcoma incidence ( J:92413 )

• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis

increased osteoma incidence ( J:92413 )

• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis

nervous system

increased neurofibrosarcoma incidence ( J:92413 )

• between 3.5 and 13.5 months,19% of mice develop malignant peripheral nerve sheath tumors when the Nf2 and Trp53 alleles are carried in cis

• however, no tumors form in mice when the Nf2 and Trp53 alleles are carried in trans

Genotype
MGI:3850390

cn3

• Allelic Composition: Nf2^tm2Gth/Nf2^tm2Gth; Tg(Mpz-cre)3Brn/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

increased fibroadenoma incidence ( J:63264 )

• 12% of mice exhibit fibroadenoma in the mammary gland

osseous metaplasia ( J:63264 )

• 30% of mice develop osseous metaplasia

increased lung adenocarcinoma incidence ( J:63264 )

• in 12% in mice

increased renal carcinoma incidence ( J:63264 )

• 18% of mice develop carcinoma in situ in the kidney

increased sarcoma incidence ( J:63264 )

• 30% of mice develop stromal sarcoma

increased neurofibrosarcoma incidence ( J:63264 )

• 6% of mice develop neurofibrosarcoma

increased osteosarcoma incidence ( J:63264 )

• in 6% of mice

increased odontoma incidence ( J:63264 )

• 6% of mice exhibit odontoma

increased Schwannoma incidence ( J:63264 , J:92413 )

• 30% of mice develop osseous metaplasia (J:63264)

• 6% of mice exhibit odontoma (J:63264)

• 35% of mice develop schwannomas (J:92413)

increased osteoma incidence ( J:63264 )

• 6% of mice develop osteoma

skeleton

abnormal tooth development ( J:63264 )

• 12% of mice exhibit odontoblastic hyperplasia

increased osteosarcoma incidence ( J:63264 )

• in 6% of mice

increased osteoma incidence ( J:63264 )

• 6% of mice develop osteoma

abnormal osteoblast morphology ( J:63264 )

• osteogenic hyperplasia in 47% of mice

nervous system

increased neurofibrosarcoma incidence ( J:63264 )

• 6% of mice develop neurofibrosarcoma

increased Schwannoma incidence ( J:63264 , J:92413 )

• 30% of mice develop osseous metaplasia (J:63264)

• 6% of mice exhibit odontoma (J:63264)

• 35% of mice develop schwannomas (J:92413)

abnormal Schwann cell morphology ( J:63264 )

• 82% of mice exhibit Schwann cell hyperplasia

renal/urinary system

increased renal carcinoma incidence ( J:63264 )

• 18% of mice develop carcinoma in situ in the kidney

abnormal renal tubule morphology ( J:63264 )

• 53% of mice exhibit renal tubular cell hyperplasia

vision/eye

cataract ( J:63264 )

• in 14% to 18% of mice, in which 50% of cases are bilateral

craniofacial

abnormal tooth development ( J:63264 )

• 12% of mice exhibit odontoblastic hyperplasia

growth/size/body

abnormal tooth development ( J:63264 )

• 12% of mice exhibit odontoblastic hyperplasia

respiratory system

increased lung adenocarcinoma incidence ( J:63264 )

• in 12% in mice

integument

increased fibroadenoma incidence ( J:63264 )

• 12% of mice exhibit fibroadenoma in the mammary gland

endocrine/exocrine glands

increased fibroadenoma incidence ( J:63264 )

• 12% of mice exhibit fibroadenoma in the mammary gland

Genotype
MGI:3850395

cn4

• Allelic Composition: Nf2^tm1Gth/Nf2^tm2Gth; Tg(Mpz-cre)3Brn/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

mortality/aging

decreased survivor rate ( J:63264 )